Pediatric Vaccines Market: USD 56.06 Billion by 2031, Growth Fueled by Multivalent Formulations and Next-Generation Vaccine Platforms, Says Mordor Intelligence

Mordor Intelligence projects the global pediatric vaccines market will grow from $42.53 billion in 2026 to $56.06 billion by 2031, a 5.68% CAGR. Growth is expected to be driven by government and NGO immunization funding, multivalent vaccine adoption, and next-generation mRNA, recombinant, viral-vector, and virus-like-particle platforms. North America remains the largest market, while Asia-Pacific is forecast to be the fastest-growing region on large birth cohorts, healthcare investment, and broader immunization coverage.

Analysis

This is not an earnings-moving data point for the listed vaccine franchises; the forecast largely reflects mature, government-funded demand already embedded in consensus. The investable issue is mix: higher-valent combination products can raise revenue per fully immunized child and improve manufacturing utilization, but tender-driven public procurement limits pricing power. GSK and Sanofi appear best positioned for incremental mix benefits given their breadth in routine pediatric schedules; PFE, MRK and GSK retain durable exposure to pneumococcal vaccination, where next-generation competitive launches—not aggregate market growth—will determine share and gross-margin outcomes.

The second-order beneficiary is not necessarily mRNA. Pediatric use requires unusually high safety, durability and schedule-integration evidence, so MRNA's platform optionality remains a long-duration R&D call rather than a 1-3 month revenue catalyst. Conversely, combination-vaccine adoption raises switching costs for standalone antigen suppliers and increases the value of reliable fill-finish, cold-chain and tender execution. Emerging-market volume can expand over 6-18 months, but it is typically lower-margin and exposed to donor budgets, currency weakness and delayed sovereign procurement.

Consensus may overvalue the stated market CAGR as a broad sector signal. Mature-market birth rates are a structural headwind, and vaccination-policy disruption or safety scrutiny can impair uptake faster than procurement budgets can offset it. The practical catalysts are pediatric schedule recommendations, CDC/ACIP and European tender decisions, competitor trial data in higher-valent pneumococcal products, and company-specific vaccine guidance; absent one of these, this release alone does not justify directional risk.

Key Decisions for Investors

• No immediate directional trade on this release; treat it as confirmation of defensive vaccine-franchise durability rather than a new estimate-revision catalyst.
• Maintain a 6-18 month quality bias toward GSK over MRNA: long GSK / short MRNA in equal dollar risk, contingent on GSK maintaining vaccine-sales guidance and MRNA lacking a pediatric program with a defined regulatory path. Thesis fails if MRNA produces superior pediatric immunogenicity/safety data or GSK loses a material tender.
• Watch PFE, MRK and GSK around higher-valent pneumococcal trial readouts and immunization-committee recommendations over the next 3-12 months. Initiate only after verified share or pricing evidence; the key falsifier is a guidance cut tied to vaccine volume, tender pricing or competitive displacement.
• For emerging-market exposure, prefer SNY or GSK only after visibility on multiyear procurement awards rather than headline market-growth forecasts. Require evidence that incremental doses are margin-accretive; low-price NGO volume and adverse FX could increase sales while diluting vaccine profitability.